Nomograms for predicting survival of patients with glioblastoma
This article has no abstract so we have provided the first paragraph of the full text.
In a previous trial conducted by the European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) Clinical Trials Group, it was shown that adjuvant temozolomide and radiotherapy can significantly increase survival time for patients with glioblastoma. Gorlia et al. conducted an exploratory subanalysis of data from this trial to investigate the prognostic factors for survival in patients with glioblastoma and to construct nomograms for the prediction of median survival times and 2-year survival probabilities for these patients.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.